Novozymes A/S (Nasdaq Copenhagen: NSIS B)

Quick Facts / Company Snapshot

Company Name: Novozymes A/S (operating as Novonesis)
Stock Exchange: Nasdaq Copenhagen
Ticker Symbol: NSIS B
Headquarters Location: Krogshoejvej 36, DK-2880 Bagsvaerd, Denmark
President and Chief Executive Officer: Ester Baiget
Chair of the Board: Cees de Jong
Total Net Sales (2025): EUR 4,157.6 million
Adjusted EBITDA (2025): EUR 1,543.3 million
Adjusted EBITDA Margin (2025): 37.1%
Net Profit (2025): EUR 583.6 million
Total Assets (2025): EUR 16,349.1 million
Total Equity (2025): EUR 10,855.2 million
Free Cash Flow Before Acquisitions (2025): EUR 770.4 million
Number of Employees: Approximately 11,000+
Number of Reportable Segments: 2
Daily Consumer Reach: More than 2 billion people every day
Total Patents Held: More than 10,000 patents
Strain Library: More than 100,000 microbial strains
Research and Development Expenses (2025): EUR 463.8 million (11.2% of net sales)
Largest Shareholder: Novo Holdings A/S (25.5% of total shares, 63.4% of votes)

Company Overview

Novozymes A/S, operating as Novonesis, functions as a highly specialized pure biology player with profound scientific capabilities in microbiology and industrial fermentation. The enterprise operates globally, engineering and delivering cutting-edge biosolutions across an exceptionally broad spectrum of industrial applications. These applications range comprehensively from advanced food and nutrition technology to agricultural enhancements, household care innovations, and transformative energy production.

The organization operates with a unified corporate purpose focused strictly on bettering the world with biology.
Biosolutions engineered by the enterprise physically reach more than two billion people every single day worldwide.
The scientific foundation of the company is built upon a vast biological library containing over 100,000 microbial strains and millions of mapped protein structures.

Driven by an unwavering ambition to generate a positive impact on both people and the planet, the enterprise strictly adheres to its comprehensive sustainability framework. By systematically leveraging nature’s own microbes, customized enzymes, and complex proteins, combined with decades of scaled fermentation expertise, the company directly addresses massive global environmental and industrial challenges.

In 2025, the enterprise successfully achieved a massive 67% reduction in absolute greenhouse gas emissions from scope 1 and 2 compared to a 2018 baseline.
Global operations were completely powered by 100% renewable electricity during the entire 2025 fiscal year.
The organization aggressively funneled 11.2% of its total net sales directly back into research and development to perpetuate its innovation pipeline.

The business model deliberately integrates advanced data analytics, machine learning, artificial intelligence, and quantum computing into its biological discovery, structural design, and performance prediction processes. This deep technological integration dramatically accelerates development cycles, allowing the organization to move with unprecedented speed from raw biological insight to highly impactful market applications. By offering affordable, value-adding biological solutions combined with the operational stability of a massive global supply chain, the enterprise effectively creates a natural operational hedge against macroeconomic volatility.

Business Segments

The corporate operational structure is systematically and deliberately divided into two highly specialized reporting segments. These distinct operational arms are meticulously aligned with specific end-market requirements, allowing the enterprise to effectively penetrate an expanding global biosolutions market while strategically capturing shares within the approximately EUR 1 trillion addressable specialty chemicals market.

Planetary Health Biosolutions

Planetary Health Biosolutions stands decisively as the largest operational segment within the enterprise. Generating EUR 2,290.3 million in net sales during the 2025 fiscal year, this massive segment accounts for a dominant 55.09% of the total consolidated corporate net sales. The division successfully delivered a robust organic sales growth of 6% year-over-year.

The segment achieved an incredibly impressive adjusted EBITDA margin of 38.2% during the 2025 fiscal year.
In the fourth quarter of 2025 alone, the segment achieved an adjusted EBITDA of EUR 200.4 million, representing a 36.4% margin.
The fundamental operational objective is to help global customers heavily reduce their reliance on fossil-based resources, harsh industrial chemicals, and excessive energy consumption.

Within this segment, the Agriculture, Energy & Tech sales area represents 65% of divisional sales, while the Household Care sales area represents the remaining 35%. Operations within Household Care strictly focus on providing biodegradable enzymes that enable consumer detergent formulations to clean effectively at lower temperatures, heavily protect delicate fabrics, and significantly extend the lifespan of clothing. The Agriculture, Energy & Tech operations deliver massive financial and environmental value by strengthening energy security and massively improving resource efficiency in heavy industrial processes.

Food & Health Biosolutions

The Food & Health Biosolutions segment functions as the secondary, yet highly critical, operational arm of the enterprise. In 2025, this segment generated EUR 1,867.3 million in net sales, strictly equating to 44.91% of the total consolidated net sales. The division demonstrated accelerated momentum by achieving a very strong organic sales growth of 8% across its global operations.

The segment recorded an adjusted EBITDA of EUR 669.4 million for the full fiscal year 2025.
The adjusted EBITDA margin for the segment stood at a highly profitable 35.8%.
The core operational focus is exclusively dedicated to improving the taste, texture, appearance, and fundamental nutritional profile of global food and beverage supply chains.

The Food & Beverages sales area completely dominates this segment, accounting for 74% of divisional sales, while the Human Health sales area comprises the remaining 26%. The operations unlock desirable consumer tastes and textures while heavily enabling the transition to cleaner, simpler ingredient labels. The division provides strictly essential starter cultures for global dairy production, making processing more consistent and cost-effective. Simultaneously, the Human Health operations engineer scientifically researched ingredients, including complex probiotics and human milk oligosaccharides (HMOs), to address critical consumer wellness demands.

History and Evolution

The enterprise possesses a profound and highly complex corporate history rooted deeply in over a century of extreme scientific expertise spanning microbiology and industrial fermentation. The modern corporate iteration was officially forged following a massive and historic statutory merger that fundamentally altered the global biotechnology landscape.

The transformative combination between Novozymes A/S and Chr. Hansen Holding A/S became officially effective on January 29, 2024.
This monumental merger successfully united two leading biotechnology pioneers to establish an unrivaled global powerhouse in biosolutions.
As a strict regulatory condition of this massive merger, the combined entity was legally required to divest a specific portion of its global lactase enzyme business.

The mandated divestment of the combined lactase enzyme business was successfully completed on November 26, 2024. The operations were completely transferred to Kerry Group plc for a total financial consideration of EUR 144.5 million, calculated net of cash. Following the swift and successful integration of the legacy corporate entities, the management team rapidly accelerated its strategic global expansion initiatives.

In 2025, the enterprise aggressively acquired dsm-firmenich’s highly lucrative sales and distribution activities within the Feed Enzyme Alliance.
This massive acquisition resulted in an immense net cash flow impact of EUR 1,519.8 million.
The full integration of the Feed Enzyme Alliance decisively unlocked the total potential of the company’s vast animal biosolutions portfolio.

The historical evolutionary trajectory of the organization is also heavily defined by its rapid, aggressive adoption of advanced digital and computational technologies. The company has systematically integrated artificial intelligence, complex machine learning algorithms, and hybrid quantum computing architectures directly into its core innovation cycles. This profound technological shift has drastically reduced the temporal friction required to accurately predict complex protein structures and fully optimize microbial strain yields.

Products and Services

The comprehensive global product portfolio leverages nature’s own microbes, highly customized enzymes, and specialized proteins to precisely address extreme physical, mechanical, and biological requirements across more than 30 distinct global industries.

Agriculture, Energy & Tech Products

Generating exactly EUR 1,488.7 million in revenue, these critical solutions account for 35.81% of the total consolidated net sales. These products aggressively support maximum industrial efficiency and absolute agricultural resilience globally.

The portfolio features highly advanced yeast biosolutions engineered specifically for long-fermentation biofuel and ethanol production cycles.
The company extensively produces next-generation phytase enzymes that fundamentally enhance critical phosphorus digestibility in mass animal feed applications.
Offerings include highly specialized, digitally integrated probiotic calculators that provide large-scale livestock producers with deep insights into feed efficiency.
The division actively engineers and provides precise biological processing aids utilized comprehensively within the highly regulated biopharma industry.

Food & Beverages Products

The company supplies critical Direct Vat Set (DVS) starter cultures that are pitched directly into massive dairy vats to guarantee consistent yogurt production.
The portfolio includes highly advanced enzyme combinations that actively functionalize plant-based proteins to significantly improve mouthfeel and emulsion stability.
Customized solutions are specifically engineered to fundamentally extend the safe shelf life of commercial baked goods.
The division formulates deeply specialized biosolutions that heavily reduce the physical requirement for artificial texturizers, refined sugar, and sodium in processed foods.

Household Care Products

Generating exactly EUR 801.6 million in revenue, these solutions equate to 19.28% of the total consolidated net sales. These enzyme-driven products are entirely fundamental to the operational performance of the global detergent and cleaning industries.

The company manufactures ultra-high-performing, fully biodegradable protease enzymes developed strictly for highly challenging, low-temperature washing conditions.
The portfolio features revolutionary next-generation freshness enzymes that completely eradicate sticky body grime and prevent the yellowing of fabrics.
Offerings include highly engineered enzymatic biosolutions that successfully replace synthetic, petrochemical-based optical brighteners.
The division actively provides specialized multi-enzyme cocktails that enable global detergent producers to drastically reduce total surfactant content by close to 30%.

Human Health Products

Generating exactly EUR 485.5 million in revenue, these highly specialized products account for 11.68% of the total consolidated net sales. This highly technical product line focuses strictly on scientifically backed human wellness and complex clinical nutrition.

The company produces advanced psychobiotics that are clinically designed to actively support stress resilience, enhance sleep quality, and regulate emotional balance.
The portfolio features exceptionally complex Human Milk Oligosaccharides (HMOs) designed strictly for critical infant formula and early life nutrition applications.
The enterprise physically engineers highly robust, spore-forming probiotics that support deep gut wellness and survive extreme manufacturing processes.
Operations include the advanced, highly controlled precision fermentation of specialized nutritional proteins targeting the medical and clinical nutrition markets.

Brand Portfolio

The organization manages its global operations through a highly strategic, scientifically credible brand architecture designed to maximize deep market penetration. While specific brand revenues are fully integrated into the overarching segment financial data, these distinct identities are universally recognized across their respective global industries.

Food & Health Brands

The brands operating within this highly regulated space are globally synonymous with extreme purity, strict consistency, and absolute safety.

Vertera® Velvet: A highly specialized commercial brand delivering exceptional barista-quality foam structure and smooth stability for non-dairy, plant-based beverages.
Galaya® Smooth: A targeted biological solution brand that, when precisely combined with specific cultures, unlocks ultra-high-protein formulations for drinking yogurts.
YoFlex®: An absolutely globally recognized brand of dairy cultures utilized extensively in mass dairy production to optimize recipes and perfect consumer texture.
DVS® (Direct Vat Set): A foundational, highly disruptive brand of starter cultures that completely eliminates the need for dairy producers to conduct multi-step bulk starter preparation.
IBme™: A consumer-focused, scientifically formulated health brand specifically launched to aggressively support healthy gut balance and alleviate complex gut discomforts.
HU58™ and SC208™: Highly specialized, proprietary probiotic brands engineered for extreme temperature and moisture stability in diverse dietary supplement formats.
ProbioBrain™: A highly awarded, clinically backed psychobiotic brand specifically marketed and distributed for advanced mental wellness and mood support applications.
µBIOM™: A deeply specialized synbiotic commercial brand actively combining the complex biological benefits of HMOs and advanced probiotics.

Planetary Health Brands

The brands driving this massive segment are globally recognized for extreme performance, absolute environmental safety, and profound industrial efficiency.

Pristine® Advance: A premium, high-performance household care brand focused strictly on extreme fabric freshness and the total biological removal of complex malodors.
Progress Go: A robust, highly resilient protease brand engineered specifically for highly challenging, cost-sensitive detergent formulations prevalent in emerging global markets.
Hiphorious: A revolutionary, next-generation animal nutrition brand focused strictly on advanced phytase enzymes to maximize nutritional absorption in commercial poultry and swine.
Innova® Eclipse-L: A premier, highly dominant bioenergy brand delivering incredibly advanced yeast solutions designed for maximum ethanol yield efficiency.
Bovacillus: A deeply specialized, highly resilient probiotic brand utilized heavily within the commercial cattle and global livestock industries to optimize herd health.

Geographical Presence

The massive corporate operational footprint is exceptionally expansive, operating through a highly resilient, intentionally decentralized global model. This structure strictly positions critical manufacturing and advanced co-creation facilities in absolute proximity to major global industrial clients, ensuring a deeply diversified geographical revenue base.

Europe, Middle East & Africa (EMEA)

Representing the absolute largest geographical revenue block, the EMEA region generated exactly EUR 1,496.7 million in net sales during 2025. This massive figure accounts for exactly 36.00% of the total consolidated corporate revenue.

The global corporate headquarters is strategically anchored in Bagsvaerd, Denmark, serving as the absolute central nervous system for executive administration and deep scientific research.
In 2025, the organization officially inaugurated a massive, state-of-the-art Dairy Application Technology Center located in Denmark to accelerate regional customer co-creation.
The company heavily expanded its African operations by opening a highly specialized Baking & Beverage Application Technology Center located in South Africa.

North America

Functioning as a profoundly critical operational hub, the North American region generated exactly EUR 1,330.4 million in net sales. This equates strictly to 32.00% of the total consolidated corporate revenue, driven heavily by advanced bioenergy and sophisticated human health markets.

The region hosts incredibly advanced, large-scale fermentation infrastructure.
The physical footprint includes a highly specialized precision fermentation manufacturing facility strategically located in Blair, United States.
This massive Blair facility is completely dedicated to producing highly complex, specialized nutritional proteins for strict clinical markets.

Asia Pacific

The rapidly expanding Asia Pacific region generated exactly EUR 789.9 million in net sales during the fiscal year. This represents exactly 19.00% of the total corporate revenue, characterized by immense growth in localized household care and agricultural solutions.

The physical power dependencies within this region are heavily supported by massive, customized renewable energy assets.
The organization maintains and completely operates a massive group captive solar project that is fully operational and deeply integrated within India.
Operations are supported by highly localized application centers designed to rapidly adapt global biological solutions to highly distinct regional dietary habits.

Latin America

The Latin American market generated exactly EUR 540.5 million in net sales. This represents exactly 13.00% of the total corporate revenue, heavily anchored by massive agricultural technology deployments and bioenergy applications. Across all regions combined, developed markets generated EUR 2,641.0 million (63.52%), while emerging markets accounted for EUR 1,516.6 million (36.48%). The global physical footprint includes more than 40 highly localized R&D, advanced application, and rapid co-creation centers worldwide.

Novozymes A:S (Nasdaq Copenhagen NSIS B) Logo

Profit and Loss

The consolidated financial trajectory for the 2025 fiscal year vividly and undeniably illustrates a massive organization successfully navigating extreme macroeconomic volatility. The enterprise aggressively extracted immense operational synergies resulting directly from its recently combined, post-merger operational structure.

Metric	2025 (EUR million)	2024 (EUR million)
Net sales	4,157.6	3,833.5
Cost of goods sold	(1,916.1)	(2,024.0)
Gross profit	2,241.5	1,809.5
Sales and distribution expenses	(688.6)	(550.9)
Research and development expenses	(463.8)	(413.2)
Administrative expenses	(223.2)	(214.6)
Other operating income	16.7	28.2
Operating profit (EBIT) before special items	882.6	659.0
Special items	(65.9)	(158.0)
Operating profit (EBIT)	816.7	501.0
Share of result in associates	(6.5)	(3.5)
Financial income	35.4	26.9
Financial expenses	(102.2)	(107.3)
Profit before tax	743.4	417.1
Tax	(159.8)	(111.3)
Net profit	583.6	305.8

Total net sales surged aggressively to EUR 4,157.6 million, fundamentally driven by a deeply robust 7% organic sales growth. The gross profit demonstrated a massive structural leap, moving from EUR 1,809.5 million to an immense EUR 2,241.5 million. This strictly yielded an adjusted gross margin of 59.1%, an incredibly impressive expansion of 240 basis points.

This profound margin expansion was fundamentally driven by massive volume-based sales leverage, significantly lower input costs, and highly strategic value-based pricing initiatives.
Total operating expenses increased predictably to EUR 1,375.6 million, heavily driven by the planned, aggressive ramp-up of commercial resources designed to capture new market share.
Special items decreased substantially to EUR 65.9 million, consisting primarily of highly complex transaction and integration expenses stemming from the Feed Enzyme Alliance acquisition.
Net profit expanded massively, almost doubling to EUR 583.6 million, which generated a highly diluted earnings per share of exactly EUR 1.25.

The effective tax rate for the reporting period normalized to a highly manageable 21.5%, vastly improved from the severely distorted 30.2% rate seen previously.

Balance Sheet

The corporate balance sheet heavily and undeniably illustrates an immensely capitalized organization deliberately and intricately structured to maintain long-term technological dominance while simultaneously funding highly aggressive inorganic growth initiatives.

Assets	Dec 31, 2025 (EUR million)	Dec 31, 2024 (EUR million)
Goodwill	6,192.9	5,605.0
Other intangible assets	4,895.5	4,419.2
Property, plant and equipment	2,998.3	2,968.3
Deferred tax assets	242.2	275.0
Other financial assets	13.6	18.7
Investments in associates	17.5	24.0
Other receivables	5.9	6.0
Total Non-current assets	14,365.9	13,316.2
Inventories	772.2	720.6
Trade receivables	716.5	665.6
Contract assets	35.9	23.6
Tax receivables	46.0	58.6
Other receivables	117.0	115.4
Other financial assets	20.3	4.0
Cash and cash equivalents	275.3	280.0
Assets held for sale	–	11.6
Total Current assets	1,983.2	1,879.4
Total Assets	16,349.1	15,195.6

Liabilities and Equity	Dec 31, 2025 (EUR million)	Dec 31, 2024 (EUR million)
Total equity	10,855.2	11,176.0
Deferred tax liabilities	1,316.1	1,255.9
Provisions	23.5	39.7
Contract liabilities	79.9	105.3
Borrowings	1,303.9	1,530.4
Other liabilities	29.2	–
Total Non-current liabilities	2,752.6	2,931.3
Borrowings	1,701.5	266.4
Trade payables	420.8	423.1
Contract liabilities	26.0	22.8
Tax payables	116.7	60.9
Other liabilities	476.3	315.1
Total Current liabilities	2,741.3	1,088.3
Total Liabilities and Equity	16,349.1	15,195.6

Total assets expanded incredibly significantly to a massive EUR 16,349.1 million. This expansion was exclusively driven by a monumental increase in Goodwill, which reached exactly EUR 6,192.9 million, and Other intangible assets, which scaled to EUR 4,895.5 million. This directly reflects the massive capitalization of acquired customer relationships and vast strain libraries.

Total liabilities increased sharply to exactly EUR 5,493.9 million.
Current borrowings skyrocketed alarmingly to EUR 1,701.5 million, driven entirely by a massive EUR 1,470 million bridge loan obtained strictly to finance the Feed Enzyme Alliance acquisition.
Total equity contracted slightly, settling at EUR 10,855.2 million, which ultimately resulted in an incredibly strong equity ratio of exactly 66.4%.

Cash Flow

The fundamental, biological business model is explicitly and deliberately designed to consistently generate incredibly strong, highly reliable free cash flows. This liquidity is strictly utilized to fund perpetual innovation, service massive debt structures, and aggressively return accumulated capital directly to shareholders.

Cash Flow Category	2025 (EUR million)	2024 (EUR million)
Cash flow from operating activities	1,221.5	1,019.9
Cash flow from investing activities	(1,970.9)	(199.7)
Cash flow from financing activities	753.3	(703.2)
Net cash flow	3.9	117.0

Operating activities provided a remarkably strong and heavily robust EUR 1,221.5 million in 2025. This massive cash generation increase was primarily and undeniably attributable to the direct surge in underlying net profit, heavily reduced cash tax payments, and highly favorable, deeply optimized working capital management strategies.

The organization aggressively utilized an immense EUR 1,970.9 million strictly for global investing activities.
The absolute vast majority of this capital, specifically EUR 1,519.8 million, was deployed directly and entirely for the monumental business acquisition of the Feed Enzyme Alliance.
Financing activities generated an artificial net cash inflow of exactly EUR 753.3 million.
This massive financing flow was heavily distorted by the massive injection of EUR 1,716.5 million in new borrowings.

These new borrowings completely overshadowed the highly aggressive cash outflows that the enterprise utilized for EUR 504.6 million in strict debt repayment, EUR 402.7 million in direct shareholder dividends, and EUR 99.9 million in aggressive share buybacks. The ultimate free cash flow before acquisitions stood incredibly strong at EUR 770.4 million.

Board of Directors and Leadership Team

The massive global enterprise is guided securely by an incredibly distinguished Board of Directors and a deeply technical Executive Leadership Team. The organization strictly maintains a rigid two-tier management structure to guarantee absolute governance transparency and operational accountability.

Ester Baiget: Serves intensely as President and Chief Executive Officer. Holding a highly technical chemical engineering degree and an MBA, she has aggressively driven transformational corporate change. She concurrently serves on the Board of the United Nations Global Compact and operates as Co-Chair of the World Economic Forum Alliance of CEO Climate Leaders.
Rainer Lehmann: Functions decisively as the Executive Vice President and Chief Financial Officer. Bringing over 20 years of intense biotechnology financial experience, he is strictly responsible for managing Global Finance, Investor Relations, complex IT infrastructures, M&A operations, and Legal frameworks.

The Board of Directors actively provides immense strategic oversight, operating securely through highly specialized committees, including the rigorous Nomination and Remuneration Committee, the strict Audit Committee, and the highly focused Innovation Committee.

Cees de Jong: Serves resolutely as Chair of the Board. He possesses extensive, decades-long experience strictly within the food ingredient and industrial biotech industries, deeply pioneering the absolute integration of sustainability into hard corporate strategies.
Heine Dalsgaard: Serves precisely as Vice Chair of the Board. He brings highly versatile experience across advanced finance and global operations, serving concurrently as the Group CFO of IVC Evidensia Ltd.
Lise Kaae: Functions securely as an Independent Board Member and the strict Chair of the Audit Committee.
Monila Kothari: Serves actively as an Independent Board Member and a dedicated Member of the Innovation Committee.
Kasim Kutay: Operates fundamentally as a Non-independent Board Member, drawing power from his position as the CEO of Novo Holdings A/S.
Kevin Lane: Functions strictly as an Independent Board Member wielding deep, global agricultural and nutritional industry experience.
Morten Otto Alexander Sommer: Serves aggressively as an Independent Board Member and the Chair of the Innovation Committee, bringing absolute, extreme academic and commercial expertise in bacterial synthetic biology.
Kim Stratton: Operates securely as an Independent Board Member.

The distinguished Board is further supported by deeply dedicated employee-elected members, guaranteeing diverse organizational representation at the absolute highest levels: Robert Nøddeskov Jensen, Lars Bo Køppler, Preben Nielsen, and Frederikke Rose Spenner.

Subsidiaries, Associates, Joint Ventures

The colossal enterprise operates efficiently through a highly complex, globally expansive web of fully consolidated subsidiaries and highly strategic joint ventures. These specific legal entities completely facilitate localized engineering excellence and permit extreme market penetration across highly regulated international borders.

Bacthera AG and Bacthera Denmark A/S: These deeply specific entities are strictly identified as joint operations operating under a precise 50% ownership structure. They are currently and officially marked as under liquidation as the parent company aggressively optimizes its structural asset portfolio.
21st.BIO A/S: A highly strategic, deeply integrated Danish associate heavily involved in massive biotechnology development. The enterprise operates this entity strictly under a 39.9% ownership structure.
Microbiogen PTY Ltd.: A highly specialized associate entity based entirely in Australia. It functions securely with a precise 23.1% direct ownership stake held by the parent company.
Tecnol s.r.l. in liquidazione: A strictly Italian associate entity, formerly known globally as Beta Renewables S.p.A., held exactly at a 10.0% ownership level.

While specific revenue contributions per individual subsidiary are seamlessly and entirely integrated into the overarching segment financial data, these entities provide the massive legal framework necessary to protect intellectual property and execute biological manufacturing locally.

Physical Properties

The immense physical infrastructure of the enterprise is systematically and aggressively engineered to support massive, highly precise industrial fermentation production. The scale of these assets acts as a profound barrier to entry against biological competitors.

The global corporate headquarters is strategically and physically positioned at Krogshoejvej 36, DK-2880 Bagsvaerd, Denmark.
This massive central facility serves as the absolute central nervous system for all global administrative functions and deep, foundational scientific research.
The company actively maintains and operates a sprawling, highly connected network of more than 40 localized R&D, advanced application, and co-creation centers worldwide.
The physical footprint strictly includes highly advanced, massive-scale precision fermentation infrastructure.

Notably, the company operates an incredibly specialized manufacturing facility strategically located in Blair, United States. This massive Blair facility is completely and exclusively dedicated to producing highly specialized, pure nutritional proteins utilizing extreme precision fermentation. Furthermore, the company’s physical power dependencies are heavily supported by diversified, physical renewable energy assets. The carrying amount of all global property, plant, and equipment stood at an immense EUR 2,998.3 million at the strict conclusion of the 2025 fiscal year.

Founders

The foundational, legal establishment of the modern corporate entity is the direct, explicit result of a monumental, historic combination rather than the singular actions of individual startup founders. The modern entity, Novonesis, was officially and legally forged through the massive statutory merger of Novozymes A/S and Chr. Hansen Holding A/S, which became irrevocably effective on January 29, 2024.

However, the deep, unbroken corporate lineage traces back through many decades of profound industrial Danish biotechnology. Novozymes A/S itself originally and historically emerged as a deeply specialized biological spin-off from the massive pharmaceutical giant Novo Industri (now globally known as Novo Nordisk). This profound history fundamentally ties the organization’s deepest roots directly to the foundational vision of the Novo Nordisk Foundation, which seeks to heavily pioneer life-saving biological sciences strictly for the ultimate betterment of society.

Parent

While Novonesis functions entirely as a massive, publicly traded entity with its own independent operational board, it operates strictly under the direct, controlling influence of its absolute largest shareholder, Novo Holdings A/S. Because Novo Holdings mathematically and legally maintains 63.4% of the absolute corporate voting rights, it effectively serves as the absolute controlling entity of the enterprise.

Novo Holdings A/S is wholly and entirely owned by the Novo Nordisk Foundation, an independent, vastly capitalized, and globally dominant Danish foundation wielding immense corporate interests. The strict, unyielding objective of the Novo Nordisk Foundation is to provide an unshakeable, exceptionally stable basis for the commercial and deep research activities of all the companies operating within the broader Novo Group, while aggressively supporting global scientific, humanitarian, and profound social causes.

Investments and Capital Expenditure Plans

The overarching organizational strategy totally and unequivocally mandates an exceptionally aggressive capital investment posture. This posture is intricately engineered to wildly scale global production capabilities and completely dominate deep technological innovation across the entire specialty chemicals market.

Capital Expenditures: In the 2025 fiscal year, the firm aggressively and decisively executed physical capital investments totaling an immense EUR 470.8 million.
This massive expenditure heavily equated to exactly 11.3% of total net sales.
These massive capital expenditures are directed entirely and strictly toward significant physical production-capacity expansion projects required to meet exploding global biological demand.
Research and Development: R&D remains structurally and fundamentally paramount to survival. The enterprise deployed a massive EUR 463.8 million directly into deep research and development expenses during 2025, representing exactly 11.2% of net sales.

This immense R&D capital strictly fuels the rapid advancement of proprietary AI algorithms, extreme quantum computing integrations, and the massive physical expansion of the incredibly valuable 100,000+ biological strain library. Furthermore, the strategic corporate mandate dictates that capital expenditure for 2026 is aggressively expected to consume between 12-14% of total sales to continue funding these massive, highly complex physical infrastructure expansions.

Shareholding Pattern

The complex equity structure of the massive organization strictly characterizes a heavily institutionalized, massively stable ownership base that is actively traded on Nasdaq Copenhagen entirely under the ticker NSIS B. The total common stock consists of exactly 468,298,646 shares, deliberately structured into two distinct classes to ruthlessly safeguard long-term strategic execution from short-term market pressures.

Class A Shares: The corporate structure includes exactly 53,743,600 A shares. Each individual A share uniquely carries exactly 20 votes.
Class B Shares: The corporate structure includes exactly 414,555,046 B shares. Each individual B share carries exactly 2 votes.

The shareholder base is incredibly expansive, boasting more than 100,000 individual registered shareholders. Institutional presence is absolute and overwhelming, with approximately 70% of all B shares held entirely and strictly outside of Denmark. Just fifty massive global institutional investors collectively hold approximately 65% of the total B shares in existence.

Novo Holdings A/S: Functions absolutely as the dominant, strict controlling shareholder. Novo Holdings securely holds exactly 100.0% of all Class A shares and exactly 15.8% of all Class B shares. This precise combination equates to 25.5% of the total outstanding share capital, granting them a massive, unassailable 63.4% of the total corporate voting rights.
Institutional and Private Investors: This broad, global group actively holds the remaining 74.5% of the total share capital, which mathematically represents just 36.6% of the total voting power.
Treasury Shares: The corporation aggressively and actively manages its own equity, securely holding exactly 2,384,632 treasury shares (representing exactly 0.5% of the total stock capital) to securely and cleanly meet obligations arising from highly lucrative employee share-based incentive programs.

Future Strategy

The aggressive corporate roadmap is rigorously, mathematically dictated by the overarching “GROW Strategy” targeting the year 2030. This deeply comprehensive, multi-year framework is meticulously designed to drive incredibly sustainable growth today while aggressively reinvesting massive capital to secure absolute biological future dominance.

The financial ambitions strictly defined for 2030 include achieving a massive 6-9% organic sales CAGR.
The enterprise strictly targets reaching an approximate 39% adjusted EBITDA margin.
The strategy demands doubling the adjusted ROIC to approximately 16% (strictly calculated excluding goodwill).

The ambitious GROW strategy is built securely and rigidly upon three unyielding, fundamental core pillars. First, “Grow the core” demands securing incredibly strong, highly profitable growth across all existing business areas by consistently and aggressively outperforming underlying end-market volume growth through strict value-based pricing and heavy global upselling. Second, “Enhance our distinctive position” requires continuously investing incredibly heavily in deep customer understanding, absolute global innovation leadership, and world-class physical scale capabilities. This involves rapidly training more than 600 corporate ambassadors strictly on advanced AI tools to radically embed artificial intelligence into every single layer of biological discovery and manufacturing. Third, “Accelerate the biosolutions market” dictates selectively funneling massive capital into highly promising adjacent markets, strictly including enzymatic plastic recycling, advanced biological carbon capture, future fuels, and specialized nutritional proteins.

Key Strengths

The incredibly deep, highly defensive competitive moat heavily surrounding the enterprise is firmly and permanently constructed upon an unassailable foundation of absolutely unmatched biological expertise and extreme global operational capacity.

The organization possesses a totally formidable, legally impenetrable intellectual property portfolio securely holding more than 10,000 active patents, strictly safeguarding its proprietary enzyme and complex microbial technologies from global competitors.
The enterprise maintains an utterly unique, historically vast biological library securely spanning hundreds of thousands of distinct microbial strains and millions of digitally mapped protein structures.
The company’s incredibly deep integration of artificial intelligence tools, including AlphaFold, allows it to predict incredibly complex protein shapes in under a minute, drastically shrinking R&D timelines and boosting industrial strain yields by up to an astonishing 300%.
Operating strictly as a pure biology player, the firm’s immense global production footprint relies entirely and absolutely on deep fermentation, providing extreme formulation flexibility, massive scale, and deeply built-in supply chain resilience.

Key Challenges and Risks

Operating deeply within highly complex, totally interconnected, and heavily regulated global supply chains automatically and unavoidably exposes the massive biological enterprise to a vast array of multifaceted, potentially severe existential risks.

Cybersecurity Threats: The highly digitized enterprise faces an incredibly increased, severe daily risk of targeted, highly sophisticated cyberattacks. A successful catastrophic breach holds the extreme potential to severely disrupt critical continuous fermentation operations, completely compromise highly sensitive, proprietary strain data, and massively damage organizational reputation.
Geopolitical and Economic Volatility: The global organization is massively and continuously exposed to rapid, unpredictable fluctuations in global trade, heavily driven by severe trade tensions, the sudden imposition of punitive tariffs, and massive physical supply-demand disruptions that inflate operational expenses.
Integration and Debt Management: The massive, heavily debt-financed acquisition of the Feed Enzyme Alliance severely and sharply increased total net interest-bearing debt to a massive EUR 2,727.8 million. This aggressively pushed the critical NIBD/EBITDA ratio to 1.9x. The company faces the strict, absolute challenge of successfully refinancing the massive EUR 1,470 million bridge loan before it officially and legally expires in 2026.

Conclusion and Strategic Outlook

Novozymes A/S (operating boldly as Novonesis) has absolutely and undeniably proven its total, unyielding capacity to systematically engineer highly profitable, biologically driven growth amidst profound, unrelenting global macroeconomic volatility. By generating an immense EUR 4,157.6 million in total net sales and securing a massively impressive EUR 1,543.3 million in adjusted EBITDA during the 2025 fiscal year, the organization has completely and totally validated the intense, structural resilience of its newly formed, post-merger, two-segment business model.

As the incredibly massive biological enterprise aggressively and systematically executes the deeply critical stages of its 2030 GROW strategy, it remains utterly and intensely focused on leveraging its massive, unparalleled biological strain libraries completely toward carving a totally dominant, unassailable position within the incredibly lucrative EUR 1 trillion specialty chemicals market. While immediate, intensely severe global challenges explicitly persist regarding rapidly shifting geopolitical trade policies and highly complex, sophisticated cybersecurity threats, the firm’s absolutely formidable, aggressively continuous investment in next-generation R&D—totaling precisely EUR 463.8 million in 2025 alone—guarantees a continuous, highly lucrative pipeline of deeply proprietary biological solutions. Anchored perfectly and absolutely by a resolute, unyielding commitment to its “People. Planet. Positive.” sustainability ambition, and heavily backed by the immense financial power of the Novo Nordisk Foundation, the enterprise is fundamentally and perfectly positioned to aggressively elevate its immense corporate value and entirely sustain its absolute dominance as a premier global biosolutions powerhouse.

FAQ Section

What is the core business of Novozymes A/S (Novonesis)?

The enterprise is a massive pure biology player with extreme scientific specialization strictly in microbiology and advanced industrial fermentation. It aggressively engineers and provides advanced biosolutions, including enzymes, cultures, probiotics, and proteins, across diverse global industries.

How was the modern Novonesis entity formed?

The modern operational company was formed directly through a monumental, highly complex statutory merger strictly between Novozymes A/S and Chr. Hansen Holding A/S, which officially became effective on January 29, 2024.

What were the total net sales for the 2025 fiscal year?

For the fiscal year officially ended December 31, 2025, the massive enterprise recorded total consolidated net sales of exactly EUR 4,157.6 million.

What are the primary segments the company operates in?

The highly complex global business is structured precisely and strictly around two main operational segments: Food & Health Biosolutions and Planetary Health Biosolutions.

What exactly is the 2030 GROW Strategy?

The GROW Strategy is the company’s aggressive long-term corporate roadmap focused strictly on three pillars: growing the core business, enhancing its distinctive market position, and accelerating the broader biosolutions market. It mathematically targets a 6-9% organic sales CAGR by 2030.

How does the company integrate artificial intelligence into operations?

The company heavily and routinely utilizes AI, including extremely advanced tools like AlphaFold, to rapidly predict complex protein structures, accelerate R&D life cycles, massively increase bacterial strain yields by up to 300%, and heavily optimize production forecasting.

Who is the absolute largest shareholder of the company?

Novo Holdings A/S serves strictly and absolutely as the largest and controlling shareholder, heavily holding 25.5% of the total outstanding share capital and commanding an immense 63.4% of the total corporate voting rights.

What are the company’s absolute climate targets?

The organization possesses a totally uncompromising target to achieve absolute net-zero GHG emissions across its entire value chain by 2050, strongly supported by a strict goal to reduce scope 1 and 2 emissions by exactly 75% by 2030.

Official Site: https://www.novonesis.com

Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.